Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals)

利妥昔单抗生物类似药（深圳万乐药业）

Report date: 2022/07/19 20:00:45

Base Information

Drug NameRituximab biosimilar (Shenzhen Main Luck Pharmaceuticals)

Drug Alias Name利妥昔单抗生物仿制药（深圳万乐药业）重组人鼠嵌合抗CD20单克隆抗体（深圳万乐药业）

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesShenzhen Main Luck Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShenzhen Main Luck Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeL01XC02